Restarting GLP-1 treatment after a break is straightforward, but your provider will likely restart your dose lower than where you left off.
If you're looking for a provider to restart with, Luma Health's semaglutide ($197/month) and tirzepatide ($297/month) include a full medical evaluation to plan your restart safely.
Whether you paused treatment intentionally, had a coverage gap, or cancelled a subscription like Fridays and are now ready to resume, restarting GLP-1 treatment isn't as simple as picking up exactly where you left off. Here's what actually happens clinically, and how to plan the transition.
Why Your Dose Usually Resets
If more than a few weeks have passed since your last dose, your provider will likely recommend restarting at a lower dose than where you stopped, rather than resuming at your previous maintenance level. This isn't overly cautious paperwork — your body's tolerance to the medication's gastrointestinal effects can diminish during a gap, and restarting at a high dose after a break meaningfully increases the risk of significant nausea or other side effects. The exact restart dose depends on how long the gap was and what your previous dose was, which is why a real provider evaluation (not a self-directed restart) matters here.
How Long a Gap Actually Matters
A gap of a week or two typically has minimal impact and your provider may let you resume close to your previous dose. A gap of several weeks to a couple of months more often means starting meaningfully lower and re-titrating up over several weeks. A gap of many months may mean essentially starting over at the initial dose. There's no universally fixed cutoff — it's a clinical judgment based on your specific history, which is exactly why this should be a provider decision rather than something to self-manage.
Come prepared with your last known dose, roughly how long you were on treatment before pausing, when your last dose was taken, and any side effects you experienced previously. This lets your new provider make an informed decision about your restart dose rather than guessing, and can meaningfully speed up getting you back on track safely.
Addressing Any Weight Regain During the Gap
Some weight regain during a treatment gap is common, since appetite signals tend to return toward baseline once the medication's effect wears off. This isn't a personal failure or a sign the medication "stopped working" — it's a predictable physiological response to stopping a chronic-disease medication, similar to what happens with many other maintenance medications. Restarting treatment typically resumes the same downward trajectory, though your provider may adjust your titration timeline based on where you're starting from.
Restarting With a Different Provider
If you're restarting with a new provider rather than the one you originally used, share your complete treatment history (medication, peak dose, duration, and any side effects) during your intake so they can make an informed restart decision. There's no need to disclose why you left your previous provider unless it's clinically relevant — the restart dose planning is what matters medically.
Planning Your Restart
- Your last known dose and approximately how long you were on it
- The approximate date of your last dose
- Any side effects or tolerance issues from before
- A real review of your treatment history, not a generic restart dose
- A titration plan tailored to your specific gap length
- Ongoing check-ins as you re-establish tolerance
Ready to restart?
Let's plan it safely.
Luma Health's providers evaluate your treatment history and plan an appropriate restart dose — $197/month for semaglutide, $297/month for tirzepatide, flat.
Get Started → Or start your free health assessmentFrequently Asked Questions
Usually not if the gap was more than a couple of weeks. Most providers restart at a lower dose and re-titrate upward to reduce the risk of significant nausea or other side effects after tolerance has diminished.
There's no fixed universal cutoff — it depends on your specific gap length and prior dose, which is why this should be a provider's clinical decision rather than a self-directed restart.
Some regain is common as appetite signals return toward baseline. This is a predictable physiological response, not a personal failure, and restarting treatment typically resumes progress.
Not unless it's clinically relevant. What matters most for your restart is your treatment history: dose, duration, timing, and any side effects.
Yes, this is a reasonable time to discuss switching (for example, from semaglutide to tirzepatide) with your provider if your goals or situation have changed since you last took GLP-1 medication.
Typically within a few business days of provider approval, similar to a first-time start, assuming your health profile is still appropriate for treatment.
References
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PubMed 35441470
- U.S. Food and Drug Administration. Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide). FDA.gov. 2025. FDA Drug Approvals Database
- Wharton S, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2022;134(1):14-19. PubMed 34775881